Company: PTPI
Filing Date: 2025-03-14
Form Type: PRER14A
Source: 0001104659-25-024012
Chunk: 39

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-14
Form: PRER14A
Chunk 39
---
 Common Stock does not increase as a result of the Reverse Stock Split.

The Reverse Stock Split May Result in Some Stockholders Owning “Odd Lots” That May Be More Difficult to Sell or Require Greater Transaction Costs per Share to Sell.

If the Reverse Stock Split
is implemented, it will increase the number of stockholders who own “odd lots” of less than 100 shares of Common Stock. A
purchase or sale of less than 100 shares of Common Stock (an “odd lot” transaction) may result in incrementally higher trading
costs through certain brokers, particularly “full service” brokers. Therefore, those stockholders who own fewer than 100 shares
of Common Stock following the Reverse Stock Split may be required to pay higher transaction costs if they sell their Common Stock.

The Reverse Stock Split May Lead to a Decrease in our Overall Market Capitalization.

The Reverse Stock Split may
be viewed negatively by the market and, consequently, could lead to a decrease in our overall market capitalization. If the per share
market price of our Common Stock does not increase in proportion to the Reverse Stock Split ratio, then the value of our Company, as measured
by our market capitalization, will be reduced. Additionally, any reduction in our market capitalization may be magnified as a result of
the smaller number of total shares of Common Stock outstanding following the Reverse Stock Split.

Effects of the Reverse Stock Split on Outstanding Warrants and Preferred Stock

In addition to
adjusting the number of shares of our Common Stock, we would adjust all shares underlying any of our outstanding shares of preferred
stock and warrants as a result of the Reverse Stock Split, as required by the terms of these securities. In particular, we would
reduce the conversion ratio for each instrument, and would increase the applicable exercise price or conversion price in accordance
with the terms of each instrument and based on the Reverse Stock Split Ratio.

<div align='center'>24</div>

The Series Warrants include a contain a Share Combination Event
Adjustment provision, conditioned upon the receipt of Stockholder Approval as more fully described in the Issuance Proposal. Issuances
of additional shares in connection with such Share Combination Event Adjustment provision could result in our shareholders suffering substantial
dilution.

The Certificate of
Designations of the Company’s Series A Preferred Stock (“Certificate of Designations” and the warrants issued
concurrently with the Series A Preferred Stock (the “Warrants”) in July 2023 pursuant to the Securities
Purchase Agreement (